论文部分内容阅读
目的:探讨替格瑞洛缓解老年女性急性冠脉综合征患者氯吡格雷抵抗的临床效果。方法:以2015年1月至10月在我院治疗并行择期冠脉介入(PCI)手术的老年女性急性冠脉综合征患者为研究对象,筛选出100例存在氯吡格雷抵抗者,将其随机分为对照组(予氯吡格雷治疗)和观察组(予替格瑞洛治疗)。观察比较两组患者术后血小板反应指数(PRI)、PRI达标率以及不良事件发生率的差异。结果:两组用药7、14和30 d后,PRI均下降,且观察组比对照组明显(P<0.05);治疗后,观察组PRI达标率为72%,明显高于对照组(44%)。两组消化道事件和呼吸困难等发生率无明显差异,观察组出血发生率明显低于对照组(P<0.05)。结论:替格瑞洛对老年女性急性冠脉综合征患者氯吡格雷抵抗有较好的缓解作用,且不良事件发生率较低。
Objective: To investigate the clinical effect of ticagrelor on alleviating clopidogrel resistance in elderly patients with acute coronary syndrome. Methods: A total of 100 elderly patients with clopidogrel resistance were selected from patients with acute coronary syndrome who underwent concurrent elective coronary intervention (PCI) in our hospital from January to October 2015. They were randomized Divided into control group (for clopidogrel treatment) and observation group (for the treatment of ticagrelor). The differences of postoperative platelet response index (PRI), PRI compliance rate and incidence of adverse events between the two groups were observed and compared. Results: After 7, 14 and 30 days, the PRI of both groups decreased, and the observation group was more obvious than the control group (P <0.05). After treatment, the PRI compliance rate was 72% in the observation group, which was significantly higher than that in the control group (44% ). There were no significant differences in the incidence of gastrointestinal events and dyspnea between the two groups. The incidence of bleeding in the observation group was significantly lower than that in the control group (P <0.05). CONCLUSION: Ticagrelor is effective in alleviating clopidogrel resistance in elderly women with acute coronary syndrome and has a lower incidence of adverse events.